Role of CD4⁺ Cytotoxic T Lymphocytes in the Control of Viral Diseases and Cancer

REFERENCES

• Mitchison NA. The carrier effect in the secondary response to hapten-protein conjugates. II. Cellular cooperation. Eur J Immunol 1971;1:18–27.
   PubMedGoogle Scholar
• Keene JA and J Forman. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med 1982;155:768–782.
   PubMed Web of Science ®Google Scholar
• Krensky AM, CS Reiss, JW Mier, Long-term human cytolytic T-cell lines allospecific for HLA-DR6 antigen are OKT4+. Proc Natl Acad Sci U S A 1982;79:2365–2369.
   PubMed Web of Science ®Google Scholar
• Fleischer B. Acquisition of specific cytotoxic activity by human T4+ T lymphocytes in culture. Nature 1984;308:365–367.
   PubMed Web of Science ®Google Scholar
• Kennedy R and E Celis. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 2008;222:129–144.
   PubMed Web of Science ®Google Scholar
• Glimcher LH and KM Murphy. Lineage commitment in the immune system: The T helper lymphocyte grows up. Genes Dev 2000;14:1693–1711.
   PubMed Web of Science ®Google Scholar
• Veldhoen M, C Uyttenhove, J van Snick, Transforming growth factor-beta ‘reprograms’ the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2008;9:1341–1346.
   PubMed Web of Science ®Google Scholar
• Dardalhon V, A Awasthi, H Kwon, IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(–) effector T cells. Nat Immunol 2008;9:1347–1355.
   PubMed Web of Science ®Google Scholar
• Chen Z and JJ O’Shea. Th17 cells: A new fate for differentiating helper T cells. Immunol Res 2008;41:87–102.
   PubMed Web of Science ®Google Scholar
• Annunziato F, L Cosmi, V Santarlasci, Phenotypic and functional features of human Th17 cells. J Exp Med 2007;204:1849–1861.
   PubMed Web of Science ®Google Scholar
• Duhen T, R Geiger, D Jarrossay, Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009;10:857–863.
   PubMed Web of Science ®Google Scholar
• Trifari S, CD Kaplan, EH Tran, Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009;10:864–871.
   PubMed Web of Science ®Google Scholar
• Fujita H, KE Nograles, T Kikuchi, Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production. Proc Natl Acad Sci U S A 2009;106:21795–21800.
   PubMed Web of Science ®Google Scholar
• Eyerich S, K Eyerich, D Pennino, Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009;119:3573–3585.
   PubMed Web of Science ®Google Scholar
• Reinhardt RL, SJ Kang, HE Liang, and RM Locksley. T helper cell effector fates—Who, how and where? Curr Opin Immunol 2006;18:271–277.
   PubMedGoogle Scholar
• King C. New insights into the differentiation and function of T follicular helper cells. Nat Rev Immunol 2009;9:757–766.
   PubMed Web of Science ®Google Scholar
• Grossman WJ, JW Verbsky, W Barchet, Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004;21:589–601.
   PubMed Web of Science ®Google Scholar
• Miyara M and S Sakaguchi. Natural regulatory T cells: Mechanisms of suppression. Trends Mol Med 2007;13:108–116.
   PubMed Web of Science ®Google Scholar
• Grossman WJ, JW Verbsky, BL Tollefsen, Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 2004;104:2840–2848.
   PubMed Web of Science ®Google Scholar
• Chen Y, VK Kuchroo, J Inobe, Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science 1994;265:1237–1240.
   PubMed Web of Science ®Google Scholar
• Godfrey DI, HR MacDonald, M Kronenberg, NKT cells: What's in a name? Nat Rev Immunol 2004;4:231–237.
   PubMed Web of Science ®Google Scholar
• Vincent MS, JE Gumperz, and MB Brenner. Understanding the function of CD1-restricted T cells. Nat Immunol 2003;4:517–523.
   PubMed Web of Science ®Google Scholar
• Kronenberg M and L Gapin. The unconventional lifestyle of NKT cells. Nat Rev Immunol 2002;2:557–568.
   PubMed Web of Science ®Google Scholar
• Suni MA, SA Ghanekar, DW Houck, CD4(+)CD8(dim) T lymphocytes exhibit enhanced cytokine expression, proliferation and cytotoxic activity in response to HCMV and HIV-1 antigens. Eur J Immunol 2001;31:2512–2520.
   PubMedGoogle Scholar
• Man S, RI Lechler, JR Batchelor, and CE Sharrock. Individual variation in the frequency of HLA class II-specific cytotoxic T lymphocyte precursors. Eur J Immunol 1990;20:847–854.
   PubMedGoogle Scholar
• Lukacher AE, LA Morrison, VL Braciale, Expression of specific cytolytic activity by H-2I region-restricted, influenza virus-specific T lymphocyte clones. J Exp Med 1985;162:171–187.
   PubMed Web of Science ®Google Scholar
• McCarthy SA and A Singer. Recognition of MHC class I allodeterminants regulates the generation of MHC class II-specific CTL. J Immunol 1986;137:3087–3092.
   PubMedGoogle Scholar
• Appay V, JJ Zaunders, L Papagno, Characterization of CD4(+) CTLs ex vivo. J Immunol 2002;168:5954–5958.
   PubMed Web of Science ®Google Scholar
• Yue FY, CM Kovacs, RC Dimayuga, HIV-1-specific memory CD4+ T cells are phenotypically less mature than cytomegalovirus-specific memory CD4+ T cells. J Immunol 2004;172:2476–2486.
   PubMedGoogle Scholar
• van de Berg PJ, EM van Leeuwen, IJ ten Berge, and R van Lier. Cytotoxic human CD4(+) T cells. Curr Opin Immunol 2008;20:339–343.
   PubMedGoogle Scholar
• Appay V. The physiological role of cytotoxic CD4(+) T-cells: The holy grail? Clin Exp Immunol 2004;138:10–13.
   PubMed Web of Science ®Google Scholar
• van Leeuwen EM, EB Remmerswaal, MT Vossen, Emergence of a CD4+CD28– granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J Immunol 2004;173:1834–1841.
   PubMedGoogle Scholar
• De Jong R, M Brouwer, B Hooibrink, The CD27– subset of peripheral blood memory CD4 +lymphocytes contains functionally differentiated T lymphocytes that develop by persistent antigenic stimulation in vivo. Eur J Immunol 1992;22:993–999.
   PubMed Web of Science ®Google Scholar
• Snyder MR, M Lucas, E Vivier, Selective activation of the c-Jun NH2-terminal protein kinase signaling pathway by stimulatory KIR in the absence of KARAP/DAP12 in CD4+ T cells. J Exp Med 2003;197:437–449.
   PubMed Web of Science ®Google Scholar
• Saez-Borderias A, M Guma, A Angulo, Expression and function of NKG2D in CD4+ T cells specific for human cytomegalovirus. Eur J Immunol 2006;36:3198–3206.
   PubMed Web of Science ®Google Scholar
• van Bergen J, A Thompson, A Van Der Slik, Phenotypic and functional characterization of CD4 T cells expressing killer Ig-like receptors. J Immunol 2004;173:6719–6726.
   PubMedGoogle Scholar
• Wolthers KC, SA Otto, SM Lens, Increased expression of CD80, CD86 and CD70 on T cells from HIV-infected individuals upon activation in vitro: regulation by CD4+ T cells. Eur J Immunol 1996;26:1700–1706.
   PubMed Web of Science ®Google Scholar
• Waldmann TA and Y Tagaya. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 1999;17:19–49.
   PubMed Web of Science ®Google Scholar
• Tortorella C, H Schulze-Koops, R Thomas, Expression of CD45RB and CD27 identifies subsets of CD4+ memory T cells with different capacities to induce B cell differentiation. J Immunol 1995;155:149–162.
   PubMed Web of Science ®Google Scholar
• Shresta S, CT Pham, DA Thomas, How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol 1998;10:581–587.
   PubMed Web of Science ®Google Scholar
• Lowin B, F Beermann, A Schmidt, and J Tschopp. A null mutation in the perforin gene impairs cytolytic T lymphocyte- and natural killer cell-mediated cytotoxicity. Proc Natl Acad Sci U S A 1994;91:11571–11575.
   PubMed Web of Science ®Google Scholar
• Hahn S, R Gehri, and P Erb. Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol Rev 1995;146:57–79.
   PubMed Web of Science ®Google Scholar
• Stalder T, S Hahn, and P Erb. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J Immunol 1994;152:1127–1133.
   PubMed Web of Science ®Google Scholar
• Vergelli M, B Hemmer, PA Muraro, Human autoreactive CD4+ T cell clones use perforin- or Fas/Fas ligand-mediated pathways for target cell lysis. J Immunol 1997;158:2756–2761.
   PubMedGoogle Scholar
• Esser MT, RD Dinglasan, B Krishnamurthy, IL-2 induces Fas ligand/Fas (CD95L/CD95) cytotoxicity in CD8+ and CD4 +T lymphocyte clones. J Immunol 1997;158:5612–5618.
   PubMedGoogle Scholar
• Williams NS and VH Engelhard. Perforin-dependent cytotoxic activity and lymphokine secretion by CD4+ T cells are regulated by CD8+ T cells. J Immunol 1997;159:2091–2099.
   PubMed Web of Science ®Google Scholar
• Kayagaki N, N Yamaguchi, M Nakayama, Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J Immunol 1999;162:2639–2647.
   PubMed Web of Science ®Google Scholar
• F Yanai, E Ishii, K Kojima, Essential roles of perforin in antigen-specific cytotoxicity mediated by human CD4+ T lymphocytes: analysis using the combination of hereditary perforin-deficient effector cells and Fas-deficient target cells. J Immunol 2003;170:2205–2213.
   PubMed Web of Science ®Google Scholar
• Brown DM, C Kamperschroer, AM Dilzer, IL-2 and antigen dose differentially regulate perforin- and FasL-mediated cytolytic activity in antigen specific CD4+ T cells. Cell Immunol 2009;257:69–79.
   PubMed Web of Science ®Google Scholar
• Mauri D and WJ Pichler. Involvement of CD80 in the generation of CD4+ cytotoxic T cells. Immunol Res 1996;15:126–140.
   PubMedGoogle Scholar
• Kebir H, K Kreymborg, I Ifergan, Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007;13:1173–1175.
   PubMed Web of Science ®Google Scholar
• Janssens W, V Carlier, B Wu, CD4+CD25+ T cells lyse antigen-presenting B cells by Fas-Fas ligand interaction in an epitope-specific manner. J Immunol 2003;171:4604–4612.
   PubMed Web of Science ®Google Scholar
• Suzuki M, A Sugimoto, A Harashima, Novel mechanisms of suppressor activity exhibited by cytotoxic regulatory T cell lines, HOZOT. Exp Hematol 2009;37:92–100.
   PubMedGoogle Scholar
• Kawamura K, N Kadowaki, T Kitawaki, and T Uchiyama. Virus-stimulated plasmacytoid dendritic cells induce CD4+ cytotoxic regulatory T cells. Blood 2006;107:1031–1038.
   PubMedGoogle Scholar
• Restifo NP, FM Marincola, Y Kawakami, Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996;88:100–108.
   PubMed Web of Science ®Google Scholar
• Khong HT and NP Restifo. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 2002;3:999–1005.
   PubMed Web of Science ®Google Scholar
• Heller KN, C Gurer, and C Munz. Virus-specific CD4+ T cells: Ready for direct attack. J Exp Med 2006;203:805–808.
   PubMedGoogle Scholar
• Mumberg D, PA Monach, S Wanderling, CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci U S A 1999;96:8633–8638.
   PubMed Web of Science ®Google Scholar
• Marsh SG, ED Albert, WF Bodmer, Nomenclature for Factors of the HLA System, 2004. Hum Immunol 2005;66:571–636.
   Google Scholar
• Foulds KE, LA Zenewicz, DJ Shedlock, Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. J Immunol 2002;168:1528–1532.
   PubMed Web of Science ®Google Scholar
• Guidotti LG and FV Chisari. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001;19:65–91.
   PubMed Web of Science ®Google Scholar
• Seder RA and R Ahmed. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol 2003;4:835–842.
   PubMed Web of Science ®Google Scholar
• Hamann D, PA Baars, MH Rep, Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 1997;186:1407–1418.
   PubMed Web of Science ®Google Scholar
• Laouar Y and IN Crispe. Functional flexibility in T cells: Independent regulation of CD4+ T cell proliferation and effector function in vivo. Immunity 2000;13:291–301.
   PubMedGoogle Scholar
• Aslan N, C Yurdaydin, J Wiegand, Cytotoxic CD4 T cells in viral hepatitis.J Viral Hepat 2006;13:505–514.
   PubMed Web of Science ®Google Scholar
• Rizzetto M. Hepatitis D: Virology, clinical and epidemiological aspects. Acta Gastroenterol Belg 2000;63:221–224.
   PubMedGoogle Scholar
• Rothstein TL, JK Wang, DJ Panka, Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature 1995;374:163–165.
   PubMed Web of Science ®Google Scholar
• Cao T, P Meuleman, I Desombere, In vivo inhibition of anti-hepatitis B virus core antigen (HBcAg) immunoglobulin G production by HBcAg-specific CD4(+) Th1-type T-cell clones in a hu-PBL-NOD/SCID mouse model. J Virol 2001;75:11449–11456.
   PubMedGoogle Scholar
• Monie A, SW Tsen, CF Hung, and TC Wu. Therapeutic HPV DNA vaccines. Expert Rev Vaccines 2009;8:1221–1235.
   PubMed Web of Science ®Google Scholar
• Bosch FX, A Lorincz, N Munoz, The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244–265.
   PubMed Web of Science ®Google Scholar
• Facchinetti V, S Seresini, R Longhi, CD4+ T cell immunity against the human papillomavirus-18 E6 transforming protein in healthy donors: Identification of promiscuous naturally processed epitopes. Eur J Immunol 2005;35:806–815.
   PubMedGoogle Scholar
• Coleman N, HD Birley, AM Renton, Immunological events in regressing genital warts. Am J Clin Pathol 1994;102:768–774.
   PubMed Web of Science ®Google Scholar
• Bontkes HJ, TD de Gruijl, AJ Van Den Muysenberg, Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int J Cancer 2000;88:92–98.
   PubMed Web of Science ®Google Scholar
• Luxton JC, R Nath, N Derias, Human papillomavirus type 16-specific T cell responses and their association with recurrence of cervical disease following treatment. J Gen Virol 2003;84:1063–1070.
   PubMedGoogle Scholar
• Gandhi MK and R Khanna. Human cytomegalovirus: Clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004;4:725–738.
   PubMed Web of Science ®Google Scholar
• Khan N, A Hislop, N Gudgeon, Herpesvirus-specific CD8 T cell immunity in old age: Cytomegalovirus impairs the response to a coresident EBV infection. J Immunol 2004;173:7481–7489.
   PubMed Web of Science ®Google Scholar
• Gamadia LE, RJ Rentenaar, RA van Lier, and IJ ten Berge. Properties of CD4(+) T cells in human cytomegalovirus infection. Hum Immunol 2004;65:486–492.
   PubMed Web of Science ®Google Scholar
• Bitmansour AD, SL Waldrop, CJ Pitcher, Clonotypic structure of the human CD4+ memory T cell response to cytomegalovirus. J Immunol 2001;167:1151–1163.
   PubMed Web of Science ®Google Scholar
• Crompton L, N Khan, R Khanna, CD4+ T cells specific for glycoprotein B from cytomegalovirus exhibit extreme conservation of T-cell receptor usage between different individuals. Blood 2008;111:2053–2061.
   PubMed Web of Science ®Google Scholar
• Hegde NR, C Dunn, DM Lewinsohn, Endogenous human cytomegalovirus gB is presented efficiently by MHC class II molecules to CD4+ CTL. J Exp Med 2005;202:1109–1119.
   PubMedGoogle Scholar
• Elkington R, NH Shoukry, S Walker, Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H. Eur J Immunol 2004;34:3216–3226.
   PubMed Web of Science ®Google Scholar
• Munz C. Epstein-Barr virus nuclear antigen 1: From immunologically invisible to a promising T cell target. J Exp Med 2004;199:1301–1304.
   PubMed Web of Science ®Google Scholar
• Paludan C, D Schmid, M Landthaler, Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 2005;307:593–596.
   PubMed Web of Science ®Google Scholar
• Gessain A, F Barin, JC Vernant, Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985;2:407–410.
   PubMed Web of Science ®Google Scholar
• Osame M, K Usuku, S Izumo, HTLV-I associated myelopathy, a new clinical entity. Lancet 1986;1:1031–1032.
   PubMed Web of Science ®Google Scholar
• Hanabuchi S, T Ohashi, Y Koya, Regression of human T-cell leukemia virus type I (HTLV-I)-associated lymphomas in a rat model: Peptide-induced T-cell immunity. J Natl Cancer Inst 2001;93:1775–1783.
   PubMedGoogle Scholar
• Venturini S, DE Mosier, DR Burton, and P Poignard. Characterization of human immunodeficiency virus type 1 (HIV-1) Gag- and Gag peptide-specific CD4(+) T-cell clones from an HIV-1-seronegative donor following in vitro immunization. J Virol 2002;76:6987–6999.
   PubMedGoogle Scholar
• Zheng N, M Fujiwara, T Ueno, Strong ability of Nef-specific CD4+ cytotoxic T cells to suppress human immunodeficiency virus type 1 (HIV-1) replication in HIV-1-infected CD4+ T cells and macrophages. J Virol 2009;83:7668–7677.
   PubMed Web of Science ®Google Scholar
• Jameson J, J Cruz, and FA Ennis. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J Virol 1998;72:8682–8689.
   PubMed Web of Science ®Google Scholar
• Hudrisier D, MB Oldstone, and JE Gairin. The signal sequence of lymphocytic choriomeningitis virus contains an immunodominant cytotoxic T cell epitope that is restricted by both H-2D(b) and H-2K(b) molecules. Virology 1997;234:62–73.
   PubMedGoogle Scholar
• Vitiello A, L Yuan, RW Chesnut, Immunodominance analysis of CTL responses to influenza PR8 virus reveals two new dominant and subdominant Kb-restricted epitopes. J Immunol 1996;157:5555–5562.
   PubMed Web of Science ®Google Scholar
• Richards KA, FA Chaves, FR Krafcik, Direct ex vivo analyses of HLA-DR1 transgenic mice reveal an exceptionally broad pattern of immunodominance in the primary HLA-DR1-restricted CD4 T-cell response to influenza virus hemagglutinin. J Virol 2007;81:7608–7619.
   PubMedGoogle Scholar
• Gelder CM, JR Lamb, and BA Askonas. Human CD4+ T-cell recognition of influenza A virus hemagglutinin after subunit vaccination. J Virol 1996;70:4787–4790.
   PubMed Web of Science ®Google Scholar
• Gelder C, M Davenport, M Barnardo, Six unrelated HLA-DR-matched adults recognize identical CD4+ T cell epitopes from influenza A haemagglutinin that are not simply peptides with high HLA-DR binding affinities. Int Immunol 1998;10:211–222.
   PubMed Web of Science ®Google Scholar
• Hung K, R Hayashi, A Lafond-Walker, The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188:2357–2368.
   PubMed Web of Science ®Google Scholar
• Pardoll DM and SL Topalian. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998;10:588–594.
   PubMed Web of Science ®Google Scholar
• Houghton AN, JS Gold, and NE Blachere. Immunity against cancer: Lessons learned from melanoma. Curr Opin Immunol 2001;13:134–140.
   PubMed Web of Science ®Google Scholar
• Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol 2001;22:269–276.
   PubMed Web of Science ®Google Scholar
• Ohminami H, M Yasukawa, S Kaneko, Fas-independent and nonapoptotic cytotoxicity mediated by a human CD4(+) T-cell clone directed against an acute myelogenous leukemia-associated DEK-CAN fusion peptide. Blood 1999;93:925–935.
   PubMed Web of Science ®Google Scholar
• Schultz ES, B Schuler-Thurner, V Stroobant, Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy. J Immunol 2004;172:1304–1310.
   PubMed Web of Science ®Google Scholar
• Takahashi T, PB Chapman, SY Yang, Reactivity of autologous CD4+ T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. J Immunol 1995;154:772–779.
   PubMedGoogle Scholar
• Darrow TL, Z Abdel-Wahab, MA Quinn-Allen, and HF Seigler. Recognition and lysis of human melanoma by a CD3+, CD4+, CD8– T-cell clone restricted by HLA-A2. Cell Immunol 1996;172:52–59.
   PubMedGoogle Scholar
• Nishimura MI, D Avichezer, MC Custer, MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte. Cancer Res 1999;59:6230–6238.
   PubMedGoogle Scholar
• Zennadi R, Z Abdel-Wahab, HF Seigler, and TL Darrow. Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells: Requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 cells. Cell Immunol 2001;210:96–105.
   PubMedGoogle Scholar
• Huarte E, J Karbach, S Gnjatic, HLA-DP4 expression and immunity to NY-ESO-1: Correlation and characterization of cytotoxic CD4+ CD25– CD8– T cell clones. Cancer Immun 2004;4:15.
   PubMedGoogle Scholar
• Toes RE, F Ossendorp, R Offringa, and CJ Melief. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999;189:753–756.
   PubMed Web of Science ®Google Scholar
• Zarour HM, WJ Storkus, V Brusic, NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res 2000;60:4946–4952.
   PubMed Web of Science ®Google Scholar
• Zeng G, CE Touloukian, X Wang, Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol 2000;165:1153–1159.
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S. CD4+ T lymphocytes: A critical component of antitumor immunity. Cancer Invest 2005;23:413–419.
   PubMed Web of Science ®Google Scholar
• Hunder NN, H Wallen, J Cao, Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008;358:2698–2703.
   PubMed Web of Science ®Google Scholar
• Muranski P and NP Restifo. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol 2009;21:200–208.
   PubMed Web of Science ®Google Scholar
• Dudley ME, J Wunderlich, MI Nishimura, Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001;24:363–373.
   PubMed Web of Science ®Google Scholar
• Porakishvili N, L Kardava, AP Jewell, Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway. Haematologica 2004;89:435–443.
   PubMed Web of Science ®Google Scholar
• Gladden AB, R Woolery, P Aggarwal, Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene 2006;25:998–1007.
   PubMed Web of Science ®Google Scholar
• Gautschi O, D Ratschiller, M Gugger, Cyclin D1 in non-small cell lung cancer: A key driver of malignant transformation. Lung Cancer 2007;55:1–14.
   PubMed Web of Science ®Google Scholar
• Gladden AB and JA Diehl. Location, location, location: The role of cyclin D1 nuclear localization in cancer. J Cell Biochem 2005;96:906–913.
   PubMed Web of Science ®Google Scholar
• Dao T, T Korontsvit, V Zakhaleva, Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells. PLoS One 2009;4:e6730.
   PubMed Web of Science ®Google Scholar
• Haque T, GM Wilkie, MM Jones, Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial. Blood 2007;110:1123–1131.
   PubMed Web of Science ®Google Scholar
• Javier RT and JS Butel. The history of tumor virology. Cancer Res 2008;68:7693–7706.
   PubMedGoogle Scholar
• Young LS and AB Rickinson. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004;4:757–768.
   PubMed Web of Science ®Google Scholar
• Merlo A, R Turrini, R Dolcetti, Adoptive cell therapy against EBV-related malignancies: A survey of clinical results. Expert Opin Biol Ther 2008;8:1265–1294.
   PubMed Web of Science ®Google Scholar
• Hislop AD, GS Taylor, D Sauce, and AB Rickinson. Cellular responses to viral infection in humans: Lessons from Epstein-Barr virus. Annu Rev Immunol 2007;25:587–617.
   PubMed Web of Science ®Google Scholar
• Haigh TA, X Lin, H Jia, EBV latent membrane proteins (LMPs) 1 and 2 as immunotherapeutic targets: LMP-specific CD4+ cytotoxic T cell recognition of EBV-transformed B cell lines. J Immunol 2008;180:1643–1654.
   PubMedGoogle Scholar
• Rooney CM, CA Smith, CY Ng, Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995;345:9–13.
   PubMed Web of Science ®Google Scholar
• Heslop HE, KS Slobod, MA Pule, Long term outcome of EBV specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010;115:925–935.
   PubMed Web of Science ®Google Scholar
• Sun Q, RL Burton, and KG Lucas. Cytokine production and cytolytic mechanism of CD4(+) cytotoxic T lymphocytes in ex vivo expanded therapeutic Epstein-Barr virus-specific T-cell cultures. Blood 2002;99:3302–3309.
   PubMed Web of Science ®Google Scholar
• Khanolkar A, H Yagita, and MJ Cannon. Preferential utilization of the perforin/granzyme pathway for lysis of Epstein-Barr virus-transformed lymphoblastoid cells by virus-specific CD4+ T cells. Virology 2001;287:79–88.
   PubMedGoogle Scholar
• Wilson AD, I Redchenko, NA Williams, and AJ Morgan. CD4+ T cells inhibit growth of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand-mediated apoptosis. Int Immunol 1998;10:1149–1157.
   PubMedGoogle Scholar
• MacArthur GJ, AD Wilson, MA Birchall, and AJ Morgan. Primary CD4+ T-cell responses provide both helper and cytotoxic functions during Epstein-Barr virus infection and transformation of fetal cord blood B cells. J Virol 2007;81:4766–4775.
   PubMedGoogle Scholar
• Adhikary D, U Behrends, A Moosmann, Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med 2006;203:995–1006.
   PubMed Web of Science ®Google Scholar
• Adhikary D, U Behrends, H Boerschmann, Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy. PLoS ONE 2007;2:e583.
   PubMed Web of Science ®Google Scholar
• Taylor GS, HM Long, TA Haigh, A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells. J Immunol 2006;177:3746–3756.
   PubMed Web of Science ®Google Scholar
• Perrine SP, O Hermine, T Small, A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007;109:2571–2578.
   PubMed Web of Science ®Google Scholar
• Feng WH, B Israel, N Raab-Traub, Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res 2002;62:1920–1926.
   PubMed Web of Science ®Google Scholar
• Israel BF and SC Kenney. Virally targeted therapies for EBV-associated malignancies. Oncogene 2003;22:5122–5130.
   PubMed Web of Science ®Google Scholar
• Long HM, J Zuo, AM Leese, CD4+ T-cell clones recognizing human lymphoma-associated antigens: Generation by in vitro stimulation with autologous Epstein-Barr virus-transformed B cells. Blood 2009;114:807–815.
   PubMed Web of Science ®Google Scholar
• Rooney CM, CA Smith, CY Ng, Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549–1555.
   PubMed Web of Science ®Google Scholar
• Su Z, MV Peluso, SH Raffegerst, The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease. Eur J Immunol 2001;31:947–958.
   PubMed Web of Science ®Google Scholar
• Omiya R, C Buteau, H Kobayashi, Inhibition of EBV-induced lymphoproliferation by CD4(+) T cells specific for an MHC class II promiscuous epitope.J Immunol 2002;169:2172–2179.
   PubMed Web of Science ®Google Scholar
• Landais E, X Saulquin, E Scotet, Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. Blood 2004;103:1408–1416.
   PubMed Web of Science ®Google Scholar
• Voo KS, T Fu, HY Wang, Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med 2004;199:459–470.
   PubMed Web of Science ®Google Scholar
• Lee SP, JM Brooks, H Al-Jarrah, CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1. J Exp Med 2004;199:1409–1420.
   PubMedGoogle Scholar
• Tellam J, G Connolly, KJ Green, Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J Exp Med 2004;199:1421–1431.
   PubMed Web of Science ®Google Scholar
• Bickham K, C Munz, ML Tsang, EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function. J Clin Invest 2001;107:121–130.
   PubMedGoogle Scholar
• Paludan C, K Bickham, S Nikiforow, Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J Immunol 2002;169:1593–1603.
   PubMed Web of Science ®Google Scholar
• Fu T, KS Voo, and RF Wang. Critical role of EBNA1-specific CD4+ T cells in the control of mouse Burkitt lymphoma in vivo. J Clin Invest 2004;114:542–550.
   PubMed Web of Science ®Google Scholar
• Mautner J, D Pich, F Nimmerjahn, Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells. Eur J Immunol 2004;34:2500–2509.
   PubMedGoogle Scholar
• Khanna R, SR Burrows, PM Steigerwald-Mullen, Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: Implications for viral persistence and tumor surveillance. Virology 1995;214:633–637.
   PubMed Web of Science ®Google Scholar
• Khanna R, SR Burrows, PM Steigerwald-Mullen, Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: Evidence for HLA-DM-independent processing. Int Immunol 1997;9:1537–1543.
   PubMedGoogle Scholar
• Long HM, TA Haigh, NH Gudgeon, CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J Virol 2005;79:4896–4907.
   PubMedGoogle Scholar
• Leung CS, TA Haigh, LK Mackay, Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display. Proc Natl Acad Sci U S A 2010;107:2165–2170.
   PubMed Web of Science ®Google Scholar
• Heller KN, F Arrey, P Steinherz, Patients with Epstein Barr virus-positive lymphomas have decreased CD4(+) T-cell responses to the viral nuclear antigen 1. Int J Cancer 2008;123:2824–2831.
   PubMed Web of Science ®Google Scholar
• Moormann AM, KN Heller, K Chelimo, Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses. Int J Cancer 2009;124:1721–1726.
   PubMedGoogle Scholar
• Lunemann JD, I Jelcic, S Roberts, EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med 2008;205:1763–1773.
   PubMed Web of Science ®Google Scholar
• Salvetti M, G Giovannoni, and F Aloisi. Epstein-Barr virus and multiple sclerosis. Curr Opin Neurol 2009;22:201–206.
   PubMed Web of Science ®Google Scholar
• Toussirot E and J Roudier. Pathophysiological links between rheumatoid arthritis and the Epstein-Barr virus: An update. Joint Bone Spine 2007;74:418–426.
   PubMedGoogle Scholar
• James JA, JB Harley, and RH Scofield. Epstein-Barr virus and systemic lupus erythematosus. Curr Opin Rheumatol 2006;18:462–467.
   PubMed Web of Science ®Google Scholar
• Demachi-Okamura A, Y Ito, Y Akatsuka, Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells. Cancer Sci 2008;99:1633–1642.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, T Nagato, M Takahara, Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells. Cancer Res 2008;68:901–908.
   PubMedGoogle Scholar
• Gudgeon NH, GS Taylor, HM Long, Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity. J Virol 2005;79:5477–5488.
   PubMed Web of Science ®Google Scholar
• Voo KS, G Peng, Z Guo, Functional characterization of EBV-encoded nuclear antigen 1-specific CD4+ helper and regulatory T cells elicited by in vitro peptide stimulation. Cancer Res 2005;65:1577–1586.
   PubMed Web of Science ®Google Scholar
• Fu Z and MJ Cannon. Functional analysis of the CD4(+) T-cell response to Epstein-Barr virus: T-cell-mediated activation of resting B cells and induction of viral BZLF1 expression. J Virol 2000;74:6675–6679.
   PubMed Web of Science ®Google Scholar
• Veronese ML, A Veronesi, E D’Andrea, Lymphoproliferative disease in human peripheral blood mononuclear cell-injected SCID mice. I. T lymphocyte requirement for B cell tumor generation. J Exp Med 1992;176:1763–1767.
   PubMedGoogle Scholar
• Johannessen I, M Asghar, and DH Crawford. Essential role for T cells in human B-cell lymphoproliferative disease development in severe combined immunodeficient mice. Br J Haematol 2000;109:600–610.
   PubMedGoogle Scholar
• Wagar EJ, MA Cromwell, LD Shultz, Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice. J Immunol 2000;165:518–527.
   PubMed Web of Science ®Google Scholar
• Nikiforow S, K Bottomly, G Miller, and C Munz. Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. J Virol 2003;77:12088–12104.
   PubMedGoogle Scholar
• June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007;117:1466–1476.
   PubMed Web of Science ®Google Scholar
• Quezada SA, TR Simpson, KS Peggs, Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010;207:637–650.
   PubMed Web of Science ®Google Scholar
• Xie Y, A Akpinarli, C Maris, Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010;207:651–667.
   PubMed Web of Science ®Google Scholar